Is there any effect of COVID-19 mRNA vaccination on electrocardiographic parameters in patients without apparent cardiovascular disease?

Ayhan Küp; Mehmet Çelik; Abdulkadi Uslu; Şeyhmus Külahçıoğlu; Elif Tükenmez Tigen; Serdar Demir; Kamil Gülşen; Servet İzci; Yeşim Uygun Kızmaz; Alper Kepez

doi:10.55665/troiamedj.1151301

Klinik Araştırma

Belirgin kardiyovasküler hastalığı olmayan hastalarda COVID-19 mRNA aşısının elektrokar-diyografik parametreler üzerinde herhangi bir etkisi var mı?

Yıl 2022, Cilt: 3 Sayı: 3, 96 - 99, 30.09.2022

Ayhan Küp Mehmet Çelik Abdulkadi Uslu Şeyhmus Külahçıoğlu Elif Tükenmez Tigen Serdar Demir Kamil Gülşen Servet İzci Yeşim Uygun Kızmaz Alper Kepez

https://doi.org/10.55665/troiamedj.1151301

Öz

Amaç: Bu çalışmanın amacı, ikinci doz COVID-19 mRNA aşılamasından sonra elektrokardiyografik değişi-klikleri değerlendirmektir. Yöntem: Çalışmaya Pfizer-BioNTech ile iki doz COVID-19 aşısı yapılan toplam 260 hasta dahil edildi. Başlangıçta ve iki doz Pfizer-BioNTech aşısından yaklaşık 1 hafta sonra kaydedilen elektrokardiyo-grafik parametreler tüm hastalar için karşılaştırıldı. Bulgular: İkinci doz COVID-19 mRNA aşılamasından sonra PR aralığı arttı ve QTc maksimum aralığı önemli ölçüde azaldı. Sırasıyla ventriküler repolarizasyonda homojen olmayan atriyal iletimi ve heterojenliği yansıttığı varsayılan P dalgası dispersiyonu ve QT dispersiyonu/Tp-e aralığı ile ilgili olarak başlangıç ve ikinci doz aşılama durumları arasında anlamlı bir fark yoktu. Sonuç: Bulgularımız, ikinci doz COVID-19 mRNA aşılamasından sonra miyokardın asemptomatik tutulumu ile ilgili herhangi bir endişe olmaması gerektiğini düşündürmektedir.

Anahtar Kelimeler

COVID-19, mRNA aşısı, miyokardit, elektrokardiyografi, P dalga dispersiyonu, QT dispersiyonu

Teşekkür

Değerli vaktinizi ayırdığınız için teşekkür ederim. Saygılarımla

Kaynakça

1. Soumya RS, Unni TG, Raghu KG. Impact of COVID-19 on the cardiovascular system: A review of available reports. Cardiovasc Drugs Ther 2021;35(3):411-25. doi: 10.1007/s10 557-020-07073-y.
2. Woo W, Kim AY, Yon DK, et al. Clinical characteristics and prognostic factors of myocarditis associated with the mRNA COVID-19 vaccine. J Med Virol 2022;94(4):1566-80. doi: 10.1002/jmv.27501.
3. Hause AM, Gee J, Baggs J, et al. COVID-19 vaccine safety in adolescents aged 12-17 years-United States, December 14, 2020-July 16, 2021. MMWR Morb Mortal Wkly Rep 2021;70(31):1053-8. doi: 10.15585/mmwr.mm7031e1.
4. Barda N, Dagan N, Ben-Shlomo Y, et al. Safety of the BNT162b2 mRNA COVID-19 vaccine in a nation-wide setting. N Engl J Med 2021;385(12):1078-90. doi: 10.1056/NEJ Moa2110475.
5. Jeet Kaur R, Dutta S, Charan J, et al. Cardiovascular adverse events reported from COVID-19 vaccines: A study based on WHO database. Int J Gen Med 2021;14:3909-27. doi: 10.2147/IJGM.S324349.
6. Matta A, Kallamadi R, Matta D, Bande D. Post-mRNA COVID-19 vaccination myocarditis. Eur J Case Rep Intern Med 2021;8(8):002769. doi: 10.12890/2021_002769.
7. Fatima M, Ahmad Cheema H, Ahmed Khan MH, et al. Development of myocarditis and pericarditis after COVID-19 vaccination in adult population: A systematic review. Ann Med Surg (Lond) 2022;76:103486. doi: 10.1016/j.amsu.2022 .103486.
8. Kindermann I, Barth C, Mahfoud F, et al. Update on myocarditis. J Am Coll Cardiol 2012;59(9):779-92. doi: 10.1016 /j.jacc.2011.09.074.
9. Castro-Torres Y, Carmona-Puerta R, Katholi RE. Ventricular repolarization markers for predicting malignant arrhythmias in clinical practice. World J Clin Cases 2015;3(8):705-20. doi: 10.12998/wjcc.v3.i8.705.
10. Tsilingiris D, Vallianou NG, Karampela I, Liu J, Dalamaga M. Potential implications of lipid nanoparticles in the pathogenesis of myocarditis associated with the use of mRNA vaccines against SARS-CoV-2. Metabol Open 2022;13:100159. doi: 10.1016/j.metop.2021.100159.
11. Fung G, Luo H, Qiu Y, Yang D, McManus B. Myocarditis. Circ Res 2016;118(3):496-514. doi: 10.1161/CIRCRES AHA.115.306573.

Is there any effect of COVID-19 mRNA vaccination on electrocardiographic parameters in patients without apparent cardiovascular disease?

Yıl 2022, Cilt: 3 Sayı: 3, 96 - 99, 30.09.2022

Ayhan Küp Mehmet Çelik Abdulkadi Uslu Şeyhmus Külahçıoğlu Elif Tükenmez Tigen Serdar Demir Kamil Gülşen Servet İzci Yeşim Uygun Kızmaz Alper Kepez

https://doi.org/10.55665/troiamedj.1151301

Öz

Objective: Electrocardiographic alterations were investigated following the second dosage of COVID-19 mRNA vaccination. Methods: A total of 260 individuals after two doses of COVID-19 vaccine with Pfizer-BioNTech were included in the study. The electrocardiographic parameters recorded at baseline and approximately one week later after two doses of Pfizer-BioNTech vaccine were compared for all patients. Results: PR interval was increased and QTc maximum interval was decreased significantly after second dose COVID-19 mRNA vaccination. Baseline and post-second dose vaccination states regarding P wave dispersion and QT dispersion/Tp-e interval which have been recognized to imply inhomogeneous atrial conduction and heterogeneity in ventricular repolarization were similar between groups. Conclusion: Our findings suggest that there should be no concern related to asymptomatic involvement of the myocardium subsequent the second dose of COVID-19 mRNA vaccination.

Anahtar Kelimeler

COVID-19, mRNA vaccine, myocarditis, electrocardiography, P wave dispersion, QT dispersion

Kaynakça

1. Soumya RS, Unni TG, Raghu KG. Impact of COVID-19 on the cardiovascular system: A review of available reports. Cardiovasc Drugs Ther 2021;35(3):411-25. doi: 10.1007/s10 557-020-07073-y.
2. Woo W, Kim AY, Yon DK, et al. Clinical characteristics and prognostic factors of myocarditis associated with the mRNA COVID-19 vaccine. J Med Virol 2022;94(4):1566-80. doi: 10.1002/jmv.27501.
3. Hause AM, Gee J, Baggs J, et al. COVID-19 vaccine safety in adolescents aged 12-17 years-United States, December 14, 2020-July 16, 2021. MMWR Morb Mortal Wkly Rep 2021;70(31):1053-8. doi: 10.15585/mmwr.mm7031e1.
4. Barda N, Dagan N, Ben-Shlomo Y, et al. Safety of the BNT162b2 mRNA COVID-19 vaccine in a nation-wide setting. N Engl J Med 2021;385(12):1078-90. doi: 10.1056/NEJ Moa2110475.
5. Jeet Kaur R, Dutta S, Charan J, et al. Cardiovascular adverse events reported from COVID-19 vaccines: A study based on WHO database. Int J Gen Med 2021;14:3909-27. doi: 10.2147/IJGM.S324349.
6. Matta A, Kallamadi R, Matta D, Bande D. Post-mRNA COVID-19 vaccination myocarditis. Eur J Case Rep Intern Med 2021;8(8):002769. doi: 10.12890/2021_002769.
7. Fatima M, Ahmad Cheema H, Ahmed Khan MH, et al. Development of myocarditis and pericarditis after COVID-19 vaccination in adult population: A systematic review. Ann Med Surg (Lond) 2022;76:103486. doi: 10.1016/j.amsu.2022 .103486.
8. Kindermann I, Barth C, Mahfoud F, et al. Update on myocarditis. J Am Coll Cardiol 2012;59(9):779-92. doi: 10.1016 /j.jacc.2011.09.074.
9. Castro-Torres Y, Carmona-Puerta R, Katholi RE. Ventricular repolarization markers for predicting malignant arrhythmias in clinical practice. World J Clin Cases 2015;3(8):705-20. doi: 10.12998/wjcc.v3.i8.705.
10. Tsilingiris D, Vallianou NG, Karampela I, Liu J, Dalamaga M. Potential implications of lipid nanoparticles in the pathogenesis of myocarditis associated with the use of mRNA vaccines against SARS-CoV-2. Metabol Open 2022;13:100159. doi: 10.1016/j.metop.2021.100159.
11. Fung G, Luo H, Qiu Y, Yang D, McManus B. Myocarditis. Circ Res 2016;118(3):496-514. doi: 10.1161/CIRCRES AHA.115.306573.

Toplam 11 adet kaynakça vardır.

Ayrıntılar

Birincil Dil	İngilizce
Konular	Sağlık Kurumları Yönetimi
Bölüm	Makaleler
Yazarlar	Ayhan Küp Mehmet Çelik 0000-0003-0364-2239 Abdulkadi Uslu 0000-0002-3022-2734 Şeyhmus Külahçıoğlu 0000-0002-6435-7821 Elif Tükenmez Tigen 0000-0003-2027-4116 Serdar Demir 0000-0001-5320-3248 Kamil Gülşen 0000-0003-1103-0013 Servet İzci 0000-0002-4021-3444 Yeşim Uygun Kızmaz 0000-0002-8208-8485 Alper Kepez 0000-0003-3868-3268
Yayımlanma Tarihi	30 Eylül 2022
Gönderilme Tarihi	30 Temmuz 2022
Yayımlandığı Sayı	Yıl 2022 Cilt: 3 Sayı: 3

Kaynak Göster

APA	Küp, A., Çelik, M., Uslu, A., Külahçıoğlu, Ş., vd. (2022). Is there any effect of COVID-19 mRNA vaccination on electrocardiographic parameters in patients without apparent cardiovascular disease?. Troia Medical Journal, 3(3), 96-99. https://doi.org/10.55665/troiamedj.1151301
AMA	Küp A, Çelik M, Uslu A, Külahçıoğlu Ş, Tükenmez Tigen E, Demir S, Gülşen K, İzci S, Uygun Kızmaz Y, Kepez A. Is there any effect of COVID-19 mRNA vaccination on electrocardiographic parameters in patients without apparent cardiovascular disease?. Troia Med J. Eylül 2022;3(3):96-99. doi:10.55665/troiamedj.1151301
Chicago	Küp, Ayhan, Mehmet Çelik, Abdulkadi Uslu, Şeyhmus Külahçıoğlu, Elif Tükenmez Tigen, Serdar Demir, Kamil Gülşen, Servet İzci, Yeşim Uygun Kızmaz, ve Alper Kepez. “Is There Any Effect of COVID-19 MRNA Vaccination on Electrocardiographic Parameters in Patients Without Apparent Cardiovascular Disease?”. Troia Medical Journal 3, sy. 3 (Eylül 2022): 96-99. https://doi.org/10.55665/troiamedj.1151301.
EndNote	Küp A, Çelik M, Uslu A, Külahçıoğlu Ş, Tükenmez Tigen E, Demir S, Gülşen K, İzci S, Uygun Kızmaz Y, Kepez A (01 Eylül 2022) Is there any effect of COVID-19 mRNA vaccination on electrocardiographic parameters in patients without apparent cardiovascular disease?. Troia Medical Journal 3 3 96–99.
IEEE	A. Küp, “Is there any effect of COVID-19 mRNA vaccination on electrocardiographic parameters in patients without apparent cardiovascular disease?”, Troia Med J, c. 3, sy. 3, ss. 96–99, 2022, doi: 10.55665/troiamedj.1151301.
ISNAD	Küp, Ayhan vd. “Is There Any Effect of COVID-19 MRNA Vaccination on Electrocardiographic Parameters in Patients Without Apparent Cardiovascular Disease?”. Troia Medical Journal 3/3 (Eylül 2022), 96-99. https://doi.org/10.55665/troiamedj.1151301.
JAMA	Küp A, Çelik M, Uslu A, Külahçıoğlu Ş, Tükenmez Tigen E, Demir S, Gülşen K, İzci S, Uygun Kızmaz Y, Kepez A. Is there any effect of COVID-19 mRNA vaccination on electrocardiographic parameters in patients without apparent cardiovascular disease?. Troia Med J. 2022;3:96–99.
MLA	Küp, Ayhan vd. “Is There Any Effect of COVID-19 MRNA Vaccination on Electrocardiographic Parameters in Patients Without Apparent Cardiovascular Disease?”. Troia Medical Journal, c. 3, sy. 3, 2022, ss. 96-99, doi:10.55665/troiamedj.1151301.
Vancouver	Küp A, Çelik M, Uslu A, Külahçıoğlu Ş, Tükenmez Tigen E, Demir S, Gülşen K, İzci S, Uygun Kızmaz Y, Kepez A. Is there any effect of COVID-19 mRNA vaccination on electrocardiographic parameters in patients without apparent cardiovascular disease?. Troia Med J. 2022;3(3):96-9.

Kapak Resmi İndir

Makale Dosyaları

Tam Metin

Bu eser Creative Commons Alıntı-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.